通过心力衰竭的现象映射,减少喷射分数,以识别具有高残留风险的子群体:维多利亚子研究
Palak Shah1, Yinggan Zheng2, Burkert Pieske3
1Inova Schar Heart and Vascular, Falls Church, VA (P.S., C.R.d.F., C.M.O.).
Circulation. Heart failure
|October 8, 2025
概括
研究人员使用多模式数据确定了心力衰竭的三个不同的小组,其中包括减少喷射率 (HFrEF) 的患者. 这些分组根据临床因素和GDF-15水平进行区分,预测HFrEF中心血管事件的不同风险.
科学领域:
- 心脏病学 心脏病学
- 生物标志物发现发现
- 临床试验 临床试验
背景情况:
- 患有心力衰竭和减少喷射率 (HFrEF) 的患者面临住院和心血管死亡的显著残留风险.
- 确定不同的患者亚组对于向治疗和HFrEF管理中的风险分层至关重要.
研究的目的:
- 利用多模式数据来识别HFrEF群体内的独特子组.
- 根据临床,心电图,心声图和蛋白质组数据来描述这些子组.
- 评估在已识别的HFrEF子组中心血管死亡或心力衰竭住院的差异剩余风险.
主要方法:
- 维多利亚子研究从564名HFrEF参与者中收集了广泛的临床和生物标记数据.
- 使用105个变量进行聚合层次聚类,确定了三个不同的HFrEF现象组.
- 考克斯回归和多项逻辑回归分析了现象组与临床结果之间的关联,在BIOSTAT-CHF队列中进行了外部验证.
主要成果:
- 确定了三种不同的HFrEF现象组:现象组1 (年轻,接受良好治疗),现象组2 (心房动,Q波) 和现象组3 (老年人,双心室功能障碍,脏疾病).
- 从Phenogroup 1到3 (HR 7.0) 观察到复合结果风险的逐步增加.
- 现象组3在外部验证中显示了类似的特征和最高的一年事件率 (41%);GDF-15是关键的差异化因素.
结论:
- 识别和验证了具有独特生物特征和差异残留风险的独特HFrEF亚群.
- 增长分化因子15 (GDF-15) 成为区分这些HFrEF现象组的最重要的蛋白质标记物.
- 这些现象组和生物标志物可能会改进未来HFrEF治疗试验的入场标准.
相关概念视频
01:30Heart Failure IV: Classification and Diagnostic Evaluation
319
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
319
01:17Pathophysiology of Heart Failure
2.9K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.9K
01:29Heart Failure II: Pathophysiology
722
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
722
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
401
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
401
01:26Heart Failure III: Clinical Manifestations
485
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
485
01:30Heart Failure V: Medical Management
218
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
218